Major updates in the biotech sector over the past four trading days were on the pipeline and regulatory front from companies like Alkermes (ALKS – Analyst Report) and Amgen (AMGN – Analyst Report) among others.Recap of the Week’s Most Important Stories1. Alkermes’ experimental schizophrenia treatment, ALKS 3831, fared well in a mid-stage study. Earlier this year, the company had said […]
Related SGNT5 NASDAQ Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 YearsPorat To Google Just One Of The Week’s Top Management Changes; Here Are 7 MoreRelated IPXLFTC Requires Divestitures in Connection With Impax Laboratories Inc.’s Proposed Acquisition of CorePharma, LLCJPM Securities Picks Through Biotech News For WinnersMylan makes $205/share bid for Perrigo; Generic firms rally(Seeking Alpha)Shares of […]
Related CLDXWhy Cowen & Co Likes Celldex Therapeutics Following Its FDA ‘Breakthrough’Biotech Stocks Moving HigherCelldex Therapeutics(Investor’s Business Daily)Related BLRXMorning Market GainersBenzinga’s Top #PreMarket GainersRoth Capital Weighs In On 5 Biotech Stocks To Watch(Seeking Alpha)As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to “focus on names with definitive catalysts.”Though […]
View All3 Best-of-Breed Small Caps: Biotech Stocks to BuyNo one can deny the performance of biotech and biopharma stocks over the last six months as they have outperformed the entire market. The sector has done so well that it has brought back that dreaded word that everyone has feared in this sector since 2000: “bubble.”Source: ©iStock.com/AlexRathsHowever, it’s shortsighted to look at […]
Once again, acquisition news made it to the headlines with Horizon Pharma (HZNP – Snapshot Report) announcing that it will be acquiring Hyperion Therapeutics (HPTX – Snapshot Report). BioMarin has hit a 52-week high on acquisition rumors. Meanwhile, it’s been an eventful week on the pipeline and regulatory front as well with companies like Conatus (CNAT – Snapshot Report), Amgen […]
Posted by Jason Zweig on Mar 30, 2015 in Blog, Featured, Posts |Image credit: Genetically modified Amflora cells, BASF, flickr Creative CommonsBy Jason Zweig11:17 am ET Mar. 27, 2015In a research note out today, Credit Suisse analysts Ravi Mehrotra, Jason Kantor, Anuj Shah and Jeremiah Shepard write that biotechnology stocks are not in a bubble but “rather in a new […]
Wikimedia CommonsThere is probably a bubble in biotech stocks. In a big note on published on Friday, analysts at Credit Suisse ask if we’re in a biotech bubble, and answer that no, it’s not a bubble, merely a “new era” for biotech stocks. Which is exactly what it sounds like when something is a bubble. Credit Suisse hinges its argument on what it […]
Akin Oyedele
Mar. 27, 2015, 8:54 AM
542
Wikimedia CommonsCredit Suisse analysts say biotechs are not in a bubble.Still, in a note Friday, the firm presents evidence for the industry being in in a bubble, and other evidence that it definitely isn’t.The signs that there’s a bubble, they wrote, are that the NYSE Biotech Index has gained 204% versus 64% for the S&P 500 since […]
Wikimedia CommonsSee AlsoAviation tracking service: Germanwings co-pilot set autopilot to the lowest possible settingFed market gurus prep rate hike amid last-minute anxietiesWe just found out who the third American was on the crashed Germanwings flightNEW YORK (Reuters) – A 4 percent decline in biotechnology stocks on Wednesday sent the Nasdaq Composite Index to its largest one-day loss in nearly a […]
Related CELGIs It Closing Time At The Biotech Bar?Weekly Options Outlook: Bulls Leave Money On The Table Despite A Week-End WinCelgene backs away from development of mAb for blood cancer(Seeking Alpha)Related ILMNIs It Closing Time At The Biotech Bar?3 Niche ETFs Breaking Out3 Excellent Biotech Stocks to Buy on the Dip – Stocks in the News(Zacks)By and large, the short […]
